Taken together, these results indicate that small molecule inhibition of SLC6A19 may provide new treatment opportunities for PKU as well as other inborn errors of metabolism characterized by the toxic accumulation of neutral amino acids. The gene discussed is SLC6A19; the disease is phenylketonuria.